Podbit · All-In with Chamath, Jason, Sacks & Friedberg
The gutting of the CDC and NIH, H-1B restrictions, and a pervasive anti-science cultural shift in the US are driving scientific talent to China and elsewhere. China is now actively recruiting top scientists from Europe and India — a talent pool that previously flowed to America.
Where this was said
At 23:00 · chapter starts 19:09
The sharpest moment in the conversation arrives when Maris raises what he considers Google's obvious strategic play: slash token prices by 80% and watch OpenAI and Anthropic's business models go 'super critical.' If an enterprise can get a basically identical product from Gemini at a fifth of the price, why wouldn't they switch? The panel explores whether OpenAI is burning investor cash Uber-style to grab market share, and whether the public markets will eventually be left holding the bag. Maris is blunt: with approximately $1 trillion in spend commitments and only $60 billion in revenue, OpenAI's IPO math relies on retail and passive funds absorbing valuations that the S&P 500 rules are already being bent to accommodate. [1] — Bill Maris "Google could arbitrarily cut token prices by 80%, making its model functionally identical to OpenAI's at a fraction of the cost — and Maris…" 24:50
The transformation gaming underwent from text-based Zork to photorealistic modern games will happen to AI within the next 5 years, per Maris.
Bill Maris compared today's AI to the Atari command-line era and predicted it would reach PlayStation-equivalent sophistication within 5 years.
Maris founded Calico, invested in Flatiron and New Limit, and remains deeply interested in longevity — but says therapeutic clinical trials are a specialist area he's stepping back from. The real prize is computational biology: simulate a human cell in silico and drug discovery accelerates exponentially.
Bill Maris's Section32 has raised 6 funds averaging ~$400M in size, with all 6 performing in the top decile.
The math is unambiguous: VC funds under $750M average 4.76x DPI versus 2.42x for funds over $1B, and represent 95% of all top-decile performers. Maris's six Section32 funds have averaged ~$400M in size and all landed in the top decile.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
When you vividly imagine something, your visual, auditory, and motor cortices light up almost identically to when it actually happens. This means daily visualization is genuine neural training — not wishful thinking.
Reality has gaps — and you fill them with stories. When you meet someone new and instantly form an impression, that's not perception, it's imagination. Recognizing this is the first step to changing the story.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.